UY37679A - Tratamiento de mucopolisacaridosis ii con iduronato-2-sulfatasa (ids) humana recombinante producida por células neurales o gliales humanas - Google Patents
Tratamiento de mucopolisacaridosis ii con iduronato-2-sulfatasa (ids) humana recombinante producida por células neurales o gliales humanasInfo
- Publication number
- UY37679A UY37679A UY0001037679A UY37679A UY37679A UY 37679 A UY37679 A UY 37679A UY 0001037679 A UY0001037679 A UY 0001037679A UY 37679 A UY37679 A UY 37679A UY 37679 A UY37679 A UY 37679A
- Authority
- UY
- Uruguay
- Prior art keywords
- human
- sulfatase
- ids
- iduronate
- glial cells
- Prior art date
Links
- 101710096421 Iduronate 2-sulfatase Proteins 0.000 title abstract 3
- 102100029199 Iduronate 2-sulfatase Human genes 0.000 title abstract 3
- 230000001537 neural effect Effects 0.000 title abstract 2
- 210000004498 neuroglial cell Anatomy 0.000 title abstract 2
- 210000003169 central nervous system Anatomy 0.000 abstract 2
- 208000022018 mucopolysaccharidosis type 2 Diseases 0.000 abstract 2
- 101000840540 Homo sapiens Iduronate 2-sulfatase Proteins 0.000 abstract 1
- 210000001175 cerebrospinal fluid Anatomy 0.000 abstract 1
- 239000000203 mixture Substances 0.000 abstract 1
- 201000002273 mucopolysaccharidosis II Diseases 0.000 abstract 1
- 210000002569 neuron Anatomy 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/66—Microorganisms or materials therefrom
- A61K35/76—Viruses; Subviral particles; Bacteriophages
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
- A61K48/005—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'active' part of the composition delivered, i.e. the nucleic acid delivered
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0043—Nose
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0085—Brain, e.g. brain implants; Spinal cord
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
- C12N15/52—Genes encoding for enzymes or proenzymes
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
- C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
- C12N15/86—Viral vectors
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
- C12N9/14—Hydrolases (3)
- C12N9/16—Hydrolases (3) acting on ester bonds (3.1)
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Y—ENZYMES
- C12Y301/00—Hydrolases acting on ester bonds (3.1)
- C12Y301/06—Sulfuric ester hydrolases (3.1.6)
- C12Y301/06013—Iduronate-2-sulfatase (3.1.6.13)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
- A61K48/0075—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the delivery route, e.g. oral, subcutaneous
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2750/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssDNA viruses
- C12N2750/00011—Details
- C12N2750/14011—Parvoviridae
- C12N2750/14111—Dependovirus, e.g. adenoassociated viruses
- C12N2750/14121—Viruses as such, e.g. new isolates, mutants or their genomic sequences
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2750/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssDNA viruses
- C12N2750/00011—Details
- C12N2750/14011—Parvoviridae
- C12N2750/14111—Dependovirus, e.g. adenoassociated viruses
- C12N2750/14132—Use of virus as therapeutic agent, other than vaccine, e.g. as cytolytic agent
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2750/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssDNA viruses
- C12N2750/00011—Details
- C12N2750/14011—Parvoviridae
- C12N2750/14111—Dependovirus, e.g. adenoassociated viruses
- C12N2750/14141—Use of virus, viral particle or viral elements as a vector
- C12N2750/14143—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Genetics & Genomics (AREA)
- General Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Zoology (AREA)
- Wood Science & Technology (AREA)
- Medicinal Chemistry (AREA)
- Biomedical Technology (AREA)
- Biotechnology (AREA)
- General Engineering & Computer Science (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- Molecular Biology (AREA)
- Biochemistry (AREA)
- Epidemiology (AREA)
- Microbiology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Virology (AREA)
- Plant Pathology (AREA)
- Biophysics (AREA)
- Physics & Mathematics (AREA)
- Neurosurgery (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Neurology (AREA)
- Dermatology (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Hematology (AREA)
- Psychology (AREA)
- Otolaryngology (AREA)
- Diabetes (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Obesity (AREA)
- Mycology (AREA)
Applications Claiming Priority (4)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201762485659P | 2017-04-14 | 2017-04-14 | |
| US201762573921P | 2017-10-18 | 2017-10-18 | |
| US201762574355P | 2017-10-19 | 2017-10-19 | |
| US201762579686P | 2017-10-31 | 2017-10-31 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| UY37679A true UY37679A (es) | 2018-11-30 |
Family
ID=63793615
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| UY0001037679A UY37679A (es) | 2017-04-14 | 2018-04-13 | Tratamiento de mucopolisacaridosis ii con iduronato-2-sulfatasa (ids) humana recombinante producida por células neurales o gliales humanas |
Country Status (12)
| Country | Link |
|---|---|
| US (2) | US11613739B2 (https=) |
| EP (1) | EP3609526A4 (https=) |
| JP (3) | JP2020516291A (https=) |
| KR (2) | KR20190139951A (https=) |
| AU (2) | AU2018253303B2 (https=) |
| BR (1) | BR112019021569A2 (https=) |
| CA (1) | CA3059441A1 (https=) |
| IL (2) | IL269892B2 (https=) |
| SG (1) | SG11201909361SA (https=) |
| TW (2) | TW202532642A (https=) |
| UY (1) | UY37679A (https=) |
| WO (1) | WO2018191666A1 (https=) |
Families Citing this family (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR20190139951A (ko) | 2017-04-14 | 2019-12-18 | 리젠엑스바이오 인크. | 인간 뉴런 또는 신경교 세포에 의해 생성된 재조합 인간 이두로네이트-2 설파타제(ids)를 이용한 뮤코다당증 ii형의 치료 |
| CN110960671A (zh) * | 2019-12-25 | 2020-04-07 | 广州中医药大学(广州中医药研究院) | Elabela多肽新用途及其药物 |
| BR112022015183A2 (pt) * | 2020-01-29 | 2022-12-20 | Regenxbio Inc | Método para tratamento de um sujeito humano diagnosticado com mucopolissacaridose tipo ii (mps ii) |
| WO2022165313A1 (en) | 2021-02-01 | 2022-08-04 | Regenxbio Inc. | Gene therapy for neuronal ceroid lipofuscinoses |
| EP4291249A2 (en) * | 2021-02-10 | 2023-12-20 | RegenxBio Inc. | Treatment of mucopolysaccharidosis ii with recombinant human iduronate-2-sulfatase (ids) |
Family Cites Families (38)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA2379166C (en) | 1999-08-09 | 2013-03-26 | Targeted Genetics Corporation | Enhancement of expression of a single-stranded, heterologous nucleotide sequence from recombinant viral vectors by designing the sequence such that it forms instrastrand base pairs |
| MX359371B (es) | 2001-11-13 | 2018-09-25 | Univ Pennsylvania | Un metodo para detectar y/o identificar secuencias del virus adeno-asociado y aislamiento de secuencias novedosas identificadas de ese modo. |
| PT1453547T (pt) | 2001-12-17 | 2016-12-28 | Univ Pennsylvania | Sequências do vírus adeno-associado (aav) do serotipo 8, vetores contendo as mesmas, e utilizações destas |
| EP2345731B1 (en) | 2003-09-30 | 2015-10-21 | The Trustees of the University of Pennsylvania | Adeno-associated virus (AAV) clades, sequences, vectors containing same, and uses thereof |
| ES2525067T3 (es) | 2005-04-07 | 2014-12-17 | The Trustees Of The University Of Pennsylvania | Método de incremento de la función de un vector de AAV |
| JP4495210B2 (ja) | 2005-06-09 | 2010-06-30 | パナソニック株式会社 | 振幅誤差補償装置及び直交度誤差補償装置 |
| GB2437893A (en) * | 2006-07-25 | 2007-11-07 | Celladon Corp | Extended antegrade epicardial coronary infusion of adeno-associated viral vectors for gene therapy |
| EP2012122A1 (en) * | 2007-07-06 | 2009-01-07 | Medigene AG | Mutated parvovirus structural proteins as vaccines |
| ES2635726T3 (es) * | 2007-06-06 | 2017-10-04 | Genzyme Corporation | Terapia génica para enfermedades de almacenamiento lisosómico |
| US8734809B2 (en) | 2009-05-28 | 2014-05-27 | University Of Massachusetts | AAV's and uses thereof |
| US8628966B2 (en) | 2010-04-30 | 2014-01-14 | City Of Hope | CD34-derived recombinant adeno-associated vectors for stem cell transduction and systemic therapeutic gene transfer |
| US8927514B2 (en) | 2010-04-30 | 2015-01-06 | City Of Hope | Recombinant adeno-associated vectors for targeted treatment |
| KR20230159646A (ko) | 2010-06-25 | 2023-11-21 | 샤이어 휴먼 지네틱 테라피즈 인크. | 이듀로네이트-2-설파타제의 cns 전달을 위한 방법들 및 조성물들 |
| WO2012057363A1 (ja) | 2010-10-27 | 2012-05-03 | 学校法人自治医科大学 | 神経系細胞への遺伝子導入のためのアデノ随伴ウイルスビリオン |
| WO2012109570A1 (en) | 2011-02-10 | 2012-08-16 | The University Of North Carolina At Chapel Hill | Viral vectors with modified transduction profiles and methods of making and using the same |
| CN105755044A (zh) | 2011-04-22 | 2016-07-13 | 加利福尼亚大学董事会 | 具有变异衣壳的腺相关病毒病毒体及其使用方法 |
| KR101158673B1 (ko) | 2011-06-24 | 2012-07-03 | 주식회사 지씨바이오 | 재조합 인간 이듀로네이트-2-설파타아제를 포함하는 조성물, 제제 및 이의 제조방법 |
| ES2857773T5 (es) | 2011-08-24 | 2024-06-04 | Univ Leland Stanford Junior | Nuevas proteínas de la cápside de AAV para la transferencia de ácidos nucleicos |
| WO2013170078A1 (en) | 2012-05-09 | 2013-11-14 | Oregon Health & Science University | Adeno associated virus plasmids and vectors |
| CA2905952A1 (en) | 2013-03-13 | 2014-10-02 | The Children's Hospital Of Philadelphia | Adeno-associated virus vectors and methods of use thereof |
| CN115120746A (zh) * | 2013-05-15 | 2022-09-30 | 明尼苏达大学董事会 | 腺相关病毒介导的基因向中枢神经系统转移 |
| ES2739288T3 (es) | 2013-09-13 | 2020-01-30 | California Inst Of Techn | Recuperación selectiva |
| CN106232618A (zh) | 2013-10-11 | 2016-12-14 | 马萨诸塞眼科耳科诊所 | 预测祖先病毒序列的方法及其用途 |
| JP6818551B2 (ja) | 2013-12-03 | 2021-01-20 | ホオキパ バイオテック ジーエムビーエイチ | Ｃｍｖワクチン |
| GB201403684D0 (en) | 2014-03-03 | 2014-04-16 | King S College London | Vector |
| DK3107562T3 (da) * | 2014-02-19 | 2019-12-16 | Bioasis Technologies Inc | P97-ids-fusionsproteiner |
| WO2015164757A1 (en) | 2014-04-25 | 2015-10-29 | Oregon Health & Science University | Methods of viral neutralizing antibody epitope mapping |
| EP3151866B1 (en) | 2014-06-09 | 2023-03-08 | Voyager Therapeutics, Inc. | Chimeric capsids |
| EP3166626B1 (en) | 2014-07-11 | 2021-04-28 | Biostrategies LC | Materials and methods for treating disorders associated with sulfatase enzymes |
| US20180185495A1 (en) * | 2014-11-10 | 2018-07-05 | Alexion Pharmaceuticals, Inc. | Therapeutic compositions of alpha-l-iduronidase, iduronate-2-sulfatase, and alpha-galactosidase a and methods of use thereof |
| MA41198A (fr) | 2014-12-18 | 2017-10-24 | Shire Human Genetic Therapies | Essais d'activité enzymatique pour i2s |
| WO2016126729A1 (en) | 2015-02-03 | 2016-08-11 | Visa International Service Association | Validation identity tokens for transactions |
| HK1256341A1 (zh) | 2015-05-15 | 2019-09-20 | 明尼苏达大学董事会 | 用於治疗性递送到中枢神经系统的腺相关物 |
| EP3101125A1 (en) * | 2015-06-05 | 2016-12-07 | Laboratorios Del Dr. Esteve, S.A. | Adenoassociated virus vectors for the treatment of mucopolysaccharidoses |
| IL258005B2 (en) * | 2015-09-17 | 2025-01-01 | Res Inst Nationwide Childrens Hospital | Methods and materials for gene therapy for beta-4,1-N-acetylgalactosaminyltransferase 2 |
| SG10201912761UA (en) | 2016-04-15 | 2020-02-27 | The Trustees Of The Univ Of Pennsyvania | Gene therapy for treating mucopolysaccharidosis type ii |
| KR20190139951A (ko) | 2017-04-14 | 2019-12-18 | 리젠엑스바이오 인크. | 인간 뉴런 또는 신경교 세포에 의해 생성된 재조합 인간 이두로네이트-2 설파타제(ids)를 이용한 뮤코다당증 ii형의 치료 |
| BR112022015183A2 (pt) | 2020-01-29 | 2022-12-20 | Regenxbio Inc | Método para tratamento de um sujeito humano diagnosticado com mucopolissacaridose tipo ii (mps ii) |
-
2018
- 2018-04-13 KR KR1020197033526A patent/KR20190139951A/ko not_active Ceased
- 2018-04-13 IL IL269892A patent/IL269892B2/en unknown
- 2018-04-13 CA CA3059441A patent/CA3059441A1/en active Pending
- 2018-04-13 JP JP2019555865A patent/JP2020516291A/ja active Pending
- 2018-04-13 KR KR1020247017405A patent/KR20240093919A/ko active Pending
- 2018-04-13 UY UY0001037679A patent/UY37679A/es not_active Application Discontinuation
- 2018-04-13 IL IL307936A patent/IL307936A/en unknown
- 2018-04-13 EP EP18783760.4A patent/EP3609526A4/en active Pending
- 2018-04-13 US US16/604,427 patent/US11613739B2/en active Active
- 2018-04-13 WO PCT/US2018/027568 patent/WO2018191666A1/en not_active Ceased
- 2018-04-13 BR BR112019021569-7A patent/BR112019021569A2/pt unknown
- 2018-04-13 AU AU2018253303A patent/AU2018253303B2/en active Active
- 2018-04-13 TW TW113148905A patent/TW202532642A/zh unknown
- 2018-04-13 SG SG11201909361S patent/SG11201909361SA/en unknown
- 2018-04-13 TW TW107112724A patent/TW201903146A/zh unknown
-
2022
- 2022-12-27 JP JP2022209169A patent/JP2023052096A/ja active Pending
-
2024
- 2024-05-09 US US18/659,404 patent/US20250051740A1/en active Pending
-
2025
- 2025-01-09 AU AU2025200141A patent/AU2025200141A1/en active Pending
- 2025-02-07 JP JP2025019080A patent/JP2025087702A/ja active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| AU2018253303A1 (en) | 2019-10-31 |
| BR112019021569A2 (pt) | 2020-05-12 |
| KR20240093919A (ko) | 2024-06-24 |
| AU2025200141A1 (en) | 2025-01-30 |
| IL269892B1 (en) | 2023-12-01 |
| IL307936A (en) | 2023-12-01 |
| US20200149019A1 (en) | 2020-05-14 |
| WO2018191666A1 (en) | 2018-10-18 |
| JP2020516291A (ja) | 2020-06-11 |
| CA3059441A1 (en) | 2018-10-18 |
| IL269892A (https=) | 2019-12-31 |
| US11613739B2 (en) | 2023-03-28 |
| AU2018253303B2 (en) | 2024-11-21 |
| SG11201909361SA (en) | 2019-11-28 |
| KR20190139951A (ko) | 2019-12-18 |
| IL269892B2 (en) | 2024-04-01 |
| TW201903146A (zh) | 2019-01-16 |
| EP3609526A1 (en) | 2020-02-19 |
| US20250051740A1 (en) | 2025-02-13 |
| JP2023052096A (ja) | 2023-04-11 |
| EP3609526A4 (en) | 2021-01-13 |
| JP2025087702A (ja) | 2025-06-10 |
| TW202532642A (zh) | 2025-08-16 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| UY37679A (es) | Tratamiento de mucopolisacaridosis ii con iduronato-2-sulfatasa (ids) humana recombinante producida por células neurales o gliales humanas | |
| Jennings et al. | Stress-induced hyperalgesia | |
| CY1125423T1 (el) | Μεθοδος in vitro διαφοροποιησης των μεσεγκεφαλικων ντοπαμινεργικων(mda)νευρωνων | |
| SI3407889T1 (sl) | Organske spojine in njihova uporaba v zdravljenju ali preprečevanju motenj centralnega živčnega sistema | |
| UY37587A (es) | Tratamiento de mucopolisacaridosis i con alfa-l-iduronidasa (idua) humana glicosilada completamente humana | |
| PH12017502153A1 (en) | Diagnostic methods for t cell therapy | |
| MX2017002089A (es) | Metodo y sistema de bloqueo selectivo de fibras nerviosas. | |
| MX2017009879A (es) | Capas de normalizacion por lotes. | |
| MX386752B (es) | Agonistas del receptor farnesoide x y usos de los mismos. | |
| EP3584709A4 (en) | PRODUCTION DEVICE ONLINE MAINTENANCE SYSTEM AND PROCESS | |
| DK3442513T3 (da) | Anvendelse af cannabidiolsyre i behandling af autismespektrumforstyrrelse og forbundne forstyrrelser | |
| MX386408B (es) | Sistema y método de mercadotecnia dirigida de preevaluación digital | |
| EA201990523A1 (ru) | НОВЫЕ СЕЛЕКТИВНЫЕ ИНГИБИТОРЫ Jak1 И ИХ ПРИМЕНЕНИЕ | |
| MX2018001112A (es) | Sistemas y metodos para comunicar representaciones de tiempo. | |
| BR112022015183A2 (pt) | Método para tratamento de um sujeito humano diagnosticado com mucopolissacaridose tipo ii (mps ii) | |
| EP3856504A4 (en) | TRANSMISSION RING WITH BLOCK AND RAIL SYSTEM | |
| FR3018569B1 (fr) | Roulement instrumente et procede de fabrication d'un tel roulement instrumente | |
| BR112019024661A2 (pt) | Isolamento de células de origem epitelial circulantes no sangue periférico | |
| CL2020001550A1 (es) | Tratamientos combinados que comprenden la administración de 1h-pirazolo[4,3-b]piridinas. | |
| MX2017011918A (es) | Animal no humano que muestra una disminucion de la funcion de las motoneuronas superiores e inferiores y de la percepcion sensorial. | |
| MX2023009118A (es) | Tratamiento de la mucopolisacaridosis ii con iduronato-2-sulfatasa (ids) humana recombinante. | |
| DK3234597T3 (da) | Proteiner af WNT-signalvejen og anvendelser deraf i diagnostik og behandling af hypopigmenteringssygdomme | |
| CO2018007096A2 (es) | Toxina botulínica para trastornos primarios del estado de ánimo y afecto utilizando un neurotransmisor | |
| CL2020002147A1 (es) | 3ß-(4-metoxibenciloxi)pregn-5-en-20-ona para su uso en el tratamiento de los trastornos relacionados con los cannabinoides. | |
| AR111467A1 (es) | Tratamiento de mucopolisacaridosis ii con iduronato-2-sulfatasa (ids) humana recombinante producida por células neurales o gliales humanas |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| RDES | Application refused |
Effective date: 20241010 |